ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
5,982.72
-0.84%
US Tech 100
21,120.40
-1.18%
Dow Jones
42,215.80
-0.70%
Brent Oil
75.505
-0.70%
Bitcoin
104,900.91
0.29%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Leap Therapeutics Inc (LPTX) Quote

Leap Therapeutics Inc

Leap Therapeutics Inc (LPTX)

NASDAQ
0.3766
-0.0157
(-4.00%)
Closed June 17 4:00PM
15 min delayed - Upgrade to Realtime
0.3879
0.0113
(3.00%)
After Hours: 7:59PM
15 min delayed - Upgrade to Realtime

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.3766
Bid
0.38
Ask
0.41
Volume
294,663
0.3802 Day's Range 0.4099
0.2223 52 Week Range 4.79
Market Cap
15.606M
Previous Close
0.3923
Open
0.3975
Last Trade
1
@
0.4
Last Trade Time
Financial Volume
$ 114,704
VWAP
0.38927
Average Volume (3m)
2,208,756
Shares Outstanding
41,439,529
Dividend Yield
-
PE Ratio
-0.24
Earnings Per Share (EPS)
-1.64
Revenue
-
Net Profit
-67.79M

About Leap Therapeutics Inc

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhib... Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.leaptx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Leap Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LPTX. The last closing price for Leap Therapeutics was $0.39. Over the last year, Leap Therapeutics shares have traded in a share price range of $ 0.2223 to $ 4.79.

Leap Therapeutics currently has 41,439,529 shares outstanding. The market capitalization of Leap Therapeutics is $16.26 million. Leap Therapeutics has a price to earnings ratio (PE ratio) of -0.24.

Ask ADVFN Intelligence (AI)

LPTX Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
May 13 2025
LPTX (-4.00%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 13 2025
LPTX (-4.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
April 01 2025
LPTX (-4.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
April 01 2025
LPTX (-4.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
April 01 2025
LPTX (-4.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
April 01 2025
LPTX (-4.00%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
March 26 2025
LPTX (-4.00%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.034-8.280565026790.41060.46330.38243178320.421466CS
4-0.0274-6.782178217820.4040.46330.323370490.39237755CS
12-0.0224-5.614035087720.3990.649990.222322087560.43272411CS
26-2.6134-87.40468227422.993.580.222314375790.59101649CS
52-1.7234-82.06666666672.14.790.22238310700.93413145CS
156-9.4974-96.18594288039.87418.60.22236212403.8865716CS
260-25.6234-98.55153846152641.70.2223100434216.62063931CS

LPTX - Frequently Asked Questions (FAQ)

What is the current Leap Therapeutics share price?
The current share price of Leap Therapeutics is $ 0.3766
How many Leap Therapeutics shares are in issue?
Leap Therapeutics has 41,439,529 shares in issue
What is the market cap of Leap Therapeutics?
The market capitalisation of Leap Therapeutics is USD 16.26M
What is the 1 year trading range for Leap Therapeutics share price?
Leap Therapeutics has traded in the range of $ 0.2223 to $ 4.79 during the past year
What is the PE ratio of Leap Therapeutics?
The price to earnings ratio of Leap Therapeutics is -0.24
What is the reporting currency for Leap Therapeutics?
Leap Therapeutics reports financial results in USD
What is the latest annual profit for Leap Therapeutics?
The latest annual profit of Leap Therapeutics is USD -67.79M
What is the registered address of Leap Therapeutics?
The registered address for Leap Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Leap Therapeutics website address?
The website address for Leap Therapeutics is www.leaptx.com
Which industry sector does Leap Therapeutics operate in?
Leap Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 19.92
(190.04%)
57.35M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.39M
EYENEyenovia Inc
$ 6.96
(134.34%)
29.94M
RBNERobin Energy Ltd
$ 10.60
(92.03%)
45.44M
RELIReliance Global Group Inc
$ 2.20
(86.44%)
19.29M
SDSTStardust Power Inc
$ 0.186
(-52.10%)
39.42M
SHOTWSafety Shot Inc
$ 0.0161
(-45.97%)
12.35k
RUNSunrun Inc
$ 5.78
(-40.04%)
120.05M
SEDGSolarEdge Technologies Inc
$ 15.94
(-33.53%)
33.14M
GOVXGeoVax Labs Inc
$ 0.8924
(-32.39%)
2.64M
PCSAProcessa Pharmaceuticals Inc
$ 0.2632
(16.93%)
575.5M
GNLNGreenlane Holdings Inc
$ 0.0104
(-16.13%)
392.94M
HCTIHealthcare Triangle Inc
$ 0.022
(-16.67%)
356.57M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.45M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 11.9373
(-7.75%)
143.55M

LPTX Discussion

View Posts
glenn1919 glenn1919 3 months ago
LPTX...........................................................p/m
👍️0
Monksdream Monksdream 4 months ago
LPTX, new 52/low
👍️0
glenn1919 glenn1919 5 months ago
LPTX.......................................................bottomplay.......................................https://stockcharts.com/h-sc/ui?s=lptx&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 5 months ago
.50s seems good for an entry after the brutal dump in some .54 
👍️0
Deano361 Deano361 5 months ago
Bad day today but when this gets the data results and they go to market on the drug, this is an easy 10x stock.
👍️0
ANTADOG ANTADOG 5 months ago
nice volume comin' in, 3,22~~, ANT
👍️0
ANTADOG ANTADOG 5 months ago
added some more, only partial fill, ANT
👍️0
ANTADOG ANTADOG 5 months ago
nice chart setup, solid 3,50 break gettin' closer, ANT
👍️0
ANTADOG ANTADOG 5 months ago
4's towards nxt update and jp conference almost a given, ANT
👍️0
ANTADOG ANTADOG 5 months ago
touchin' 3's again, so little vol needed, nxt update should be saweet imvho ANT
👍️0
ANTADOG ANTADOG 6 months ago
touched 3 again, small prelude of things to come, imosho ANT
👍️0
ANTADOG ANTADOG 6 months ago
hearin' some good things comin' our way, hmm, u got to pay to play, ANT
👍️0
ANTADOG ANTADOG 6 months ago
Added 2,96~~ ANT
👍️0
ANTADOG ANTADOG 6 months ago
3,40~~ because they know... ANT
👍️0
ANTADOG ANTADOG 6 months ago
accumulated a nice amount around 3 bucks, longterm, ANT
👍️0
ANTADOG ANTADOG 6 months ago
3,35~~ ANT
👍️0
ANTADOG ANTADOG 6 months ago
3,33~~ ANT
👍️0
ANTADOG ANTADOG 6 months ago
Volume intact, ANT
👍️0
ANTADOG ANTADOG 6 months ago
hooverin' above 3 bucks, ceo certainly gave them somethin' to think about, to be continued.... ANT
👍️0
ANTADOG ANTADOG 6 months ago
3,33~~ ANT
👍️0
ANTADOG ANTADOG 6 months ago
3,24~~ ANT
👍️0
ANTADOG ANTADOG 6 months ago
3,19~~ ANT
👍️0
ANTADOG ANTADOG 6 months ago
mm in trouble lol, ANT
👍️0
ANTADOG ANTADOG 6 months ago
3,12~~ ANT
👍️0
ANTADOG ANTADOG 6 months ago
3,10 break is close, hmm, ANT
👍️0
ANTADOG ANTADOG 6 months ago
added some 2,80's, likin' the chart, ANT
👍️0
glenn1919 glenn1919 7 months ago
LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
ANTADOG ANTADOG 7 months ago
And some more 3,25's longterm, ANT
👍️0
ANTADOG ANTADOG 7 months ago
added 3,70 ANT
👍️0
ANTADOG ANTADOG 7 months ago
held first support, startin' to like this one more and more, gild support, fyi ANT
👍️0
ANTADOG ANTADOG 7 months ago
added first support, ANT
👍️0
ANTADOG ANTADOG 8 months ago
consistent buyin' often means deeper pockets like what they see or are about to find out, so they add while it's cheap, imo but we'll see soon, ANT
👍️0
ANTADOG ANTADOG 8 months ago
puppy's goin' for a new 52wk high imo ANT
👍️0
ANTADOG ANTADOG 8 months ago
because it's a double digitland stock, xcellent results will propel it imosho ANT
👍️0
joelawyer joelawyer 8 months ago
Any clue what's driving this major upside move the last week?

👍️0
glenn1919 glenn1919 8 months ago
LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 8 months ago
LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 months ago
LPTX under $3
👍️0
Monksdream Monksdream 11 months ago
LPTX under $3
👍️0
Monksdream Monksdream 11 months ago
LPTX under $2
👍️0
Monksdream Monksdream 1 year ago
LPTX under $5
👍️0
glenn1919 glenn1919 1 year ago
LPTX...................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
LPTX 10Q due March 12
👍️0
glenn1919 glenn1919 2 years ago
LPTX.......................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 years ago
LPTX................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 years ago
LPTX new 52 week low
👍️0
Monksdream Monksdream 2 years ago
LPTX new 52 week low
👍️0
Slicky1315 Slicky1315 2 years ago
Wow..almost a year and no one posted anything!!
👍️0
VivaLasVegas VivaLasVegas 3 years ago
No one in their right mind gives 2 Sheets what some joke analyst gives for any price target

They are Shills
👍️0
stockguard stockguard 3 years ago
LPTX Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update Jan. 23
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Leap Therapeutics (LPTX) to $6 from $5 and keeps an Overweight rating on the shares. Following the ASCO GI update for DKN-01, Leap hosted a conference call on Friday to walk through the data and lay out potential next steps, the analyst notes. When considering potential treatment effect, Catanzaro thinks the signal in DKK1-high patients looks even more compelling. Leap believes it could initiate a small randomized Phase II as part of the current IND that could generate data in 2023, while simultaneously engaging regulatory agencies on registrational strategies. Most notably, BeiGene's (BGNE) opt-in decision for Asian rights will almost certainly be a 2022 event, and the analyst continues to believe the ASCO GI update should make that a straightforward choice.
👍️0

Your Recent History

NASDAQ
LPTX
Leap Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads